These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28899970)

  • 1. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
    Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
    Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
    Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
    Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
    Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
    Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
    Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
    Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
    Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
    Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
    DiPippo VA; Nguyen HM; Brown LG; Olson WC; Vessella RL; Corey E
    Prostate; 2016 Feb; 76(3):325-34. PubMed ID: 26585210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
    Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
    He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
    Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
    Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
    J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.